We also show that minimal to absent NF1 immunoreactivity is a poor prognostic marker in IDH-wildtype glioblastoma, but the underlying molecular mechanisms leading to decreased NF1 expression in NF1-wildtype GBM require further investigation. The gene discussed is NF1; the disease is glioblastoma.